<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654628</url>
  </required_header>
  <id_info>
    <org_study_id>0653A-172</org_study_id>
    <secondary_id>2008_010</secondary_id>
    <nct_id>NCT00654628</nct_id>
  </id_info>
  <brief_title>Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)</brief_title>
  <acronym>BRAVO</acronym>
  <official_title>Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of
      ezetimibe/simvastatin in patients newly diagnosed with dyslipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2007</start_date>
  <completion_date type="Actual">July 1, 2009</completion_date>
  <primary_completion_date type="Actual">July 1, 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 6-week Treatment.</measure>
    <time_frame>Baseline and week 6</time_frame>
    <description>Goal attainment percentage of LDL-C after 6-week treatment. LDL-C goal attainment was based on National Cholesterol Education program (NCEP) Adult Treatment Panel (ATP) III guidelines (2004). Newly Diagnosed Dyslipidemia Patients Including: 1)Intermediate Risk (&gt;2 Risk Factors) with Total Cholesterol above 200 mg/dL or Low Density Lipoprotein C (LDL-C) level &gt;130 who failed a 3-month diet control period, or 2) high risk patients with a history of coronary artery disease or diabetes having a total cholesterol &gt;200 mg/dl or LDL-C level &gt;130 mg/dl.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 12-week Treatment.</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>Goal attainment percentage of LDL-C after 12-week treatment. LDL-C goal attainment was based on National Cholesterol Education program (NCEP) Adult Treatment Panel (ATP) III guidelines (2004). Newly Diagnosed Dyslipidemia Patients Including: 1)Intermediate Risk (&gt;2 Risk Factors) with Total Cholesterol above 200 mg/dL or Low Density Lipoprotein C (LDL-C) level &gt;130 who failed a 3-month diet control period, or 2) high risk patients with a history of coronary artery disease or diabetes having a total cholesterol &gt;200 mg/dl or LDL-C level &gt;130 mg/dl.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6</measure>
    <time_frame>Baseline and week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 6</measure>
    <time_frame>Baseline and week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 6</measure>
    <time_frame>Baseline and week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change of Triglycerides From Baseline at Week 6</measure>
    <time_frame>Baseline and week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change of Triglycerides From Baseline at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6</measure>
    <time_frame>Baseline and week 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">173</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with intermediate or high risk dyslipidemia will be enrolled to receive treatment with Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe (+) simvastatin</intervention_name>
    <description>Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Vytorin®</other_name>
    <other_name>MK653A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male Or Female Patient, 20 Through 79 Years Of Age

          -  Newly Diagnosed Dyslipidemia Patients Including: 1) Intermediate Risk (&gt;2 Risk
             Factors) With Total Cholesterol level above 200 mg/dL Or Low Density Lipoprotein-C
             (LDL-C) level&gt; 130 mg/dLwho failed a 3-Month diet control period, or 2) High Risk
             Patients with history of Coronary artery disease Or diabetes and having a total
             Cholesterol&gt; 200 mg/dL Or LDL-C level&gt; 130 mg/dL

          -  Willing To Follow An National Cholesterol Education Program (NCEP) Therapeutic
             Lifestyle Changes (TLC) Or Similar Cholesterol-Lowering Diet For The Duration Of The
             Study

          -  Female Patients Receiving Hormone Therapy (Including Hormone Replacement Therapy, And
             Estrogen Antagonist/Agonist, Or Oral Contraceptives) If Maintained On A Stable Dose
             And Regimen For At Least 8 Weeks Prior To Visit 1 And If Willing To Continue The Same
             Regimen Throughout The Study

        Exclusion Criteria:

          -  Women Who Are Pregnant Or Lactating

          -  Has A History Of Cancer Within The Past 5 Years (Except For Dermatological Basal Cell
             Or Squamous Cell Carcinoma)

          -  Patients Hypersensitive To Simvastatin Or Ezetimibe

          -  Any Condition Or Situation Which, In The Opinion Of The Investigator, Might Pose A
             Risk To The Patient Or Confound The Results Of The Study

          -  History Of Mental Instability, Drug/Alcohol Abuse Within The Past 5 Years, Or Major
             Psychiatric Illness Not Adequately Controlled By Pharmacotherapy

          -  Nephritic Syndrome Or Other Clinically Significant Renal Disease Resulting In Impaired
             Renal Function, Defined As Serum Creatinine ≧ 1.5 Mg/Dl

          -  Alanine Aminotransferase (ALT), And Aspartate Aminotransferase (AST) above 1.5 X Upper
             Limit Of Normal (Uln) Or With Active Liver Disease

          -  Congestive Heart Failure (New York Heart Association (NYHA) III Or IV), Uncontrolled
             Cardiac Arrythmias, Uncontrolled Hypertension (Systolic Blood Pressure (SBP) &gt;160 mm
             Hg Or Diastolic Blood Pressure (DBP) &gt;100 mm Hg), Unstable Angina Pectoris Or Severe
             Peripheral Artery Disease, Or Experienced Myocardial Infarction, Coronary Artery
             Bypass Surgery, Angioplasty Within 3 Months

          -  Unstable Diabetes Mellitus Patient (Hemoglobin A1c (HbA1c) &gt; 8.5%) Or Newly Diagnosed
             (Within 3 Months) Or A Change In Anti-Diabetic Pharmacotherapy Within 3 Months Of
             Screening

          -  Secondary Dyslipidemia (E.G., Hypothyroidism)

          -  Disorders Of The Hematologic, Digestive, Or Central Nervous Systems Including
             Cerebrovascular Disease And Degenerative Disease That Would Limit Study Evaluation Or
             Participation

          -  History Of Active Or Chronic Hepatobiliary Disease Or Cholelithiasis But Have Not
             Undergone Cholecystectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>(MedWatch - FDA maintained medical product safety Information)</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>(Merck: Patient &amp; Caregiver U.S. Product Web Site)</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2008</study_first_submitted>
  <study_first_submitted_qc>April 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2008</study_first_posted>
  <results_first_submitted>July 30, 2010</results_first_submitted>
  <results_first_submitted_qc>July 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2010</results_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited between August 2007 and July 2009.
In one site, 60 patients among the total 152 study population entered into the 6-week extension period after completing the base period for longer follow-up as per IRB requirement in that site.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe/Simvastatin 10/20 mg</title>
          <description>Ezetimibe/Simvastatin 10/20 mg tablet, once daily for the 6-week period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>6-week Active Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="173"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transferred to branch hospital</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Out of window period</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>6 –Week Extension Period (Single Site)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60">Subjects who completed the first 6-week period and participated in the second 6-week study period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetimibe/Simvastatin 10/20 mg</title>
          <description>Ezetimibe/Simvastatin 10/20 mg tablet, once daily for the 6-week period</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="173"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.5" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline value of Low Density Lipoprotein-C</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156.8" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline value of Total Cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="243.7" spread="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline value of High Density Lipoprotein-C</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.1" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline value of Triglycerides</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145" lower_limit="89" upper_limit="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sitting Diastolic Blood Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.5" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sitting Systolic Blood Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133.3" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 6-week Treatment.</title>
        <description>Goal attainment percentage of LDL-C after 6-week treatment. LDL-C goal attainment was based on National Cholesterol Education program (NCEP) Adult Treatment Panel (ATP) III guidelines (2004). Newly Diagnosed Dyslipidemia Patients Including: 1)Intermediate Risk (&gt;2 Risk Factors) with Total Cholesterol above 200 mg/dL or Low Density Lipoprotein C (LDL-C) level &gt;130 who failed a 3-month diet control period, or 2) high risk patients with a history of coronary artery disease or diabetes having a total cholesterol &gt;200 mg/dl or LDL-C level &gt;130 mg/dl.</description>
        <time_frame>Baseline and week 6</time_frame>
        <population>Intention-To-Treat (ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin 10/20 mg</title>
            <description>Ezetimibe/Simvastatin 10/20 mg tablet, once daily for the 6-week period</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 6-week Treatment.</title>
          <description>Goal attainment percentage of LDL-C after 6-week treatment. LDL-C goal attainment was based on National Cholesterol Education program (NCEP) Adult Treatment Panel (ATP) III guidelines (2004). Newly Diagnosed Dyslipidemia Patients Including: 1)Intermediate Risk (&gt;2 Risk Factors) with Total Cholesterol above 200 mg/dL or Low Density Lipoprotein C (LDL-C) level &gt;130 who failed a 3-month diet control period, or 2) high risk patients with a history of coronary artery disease or diabetes having a total cholesterol &gt;200 mg/dl or LDL-C level &gt;130 mg/dl.</description>
          <population>Intention-To-Treat (ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 12-week Treatment.</title>
        <description>Goal attainment percentage of LDL-C after 12-week treatment. LDL-C goal attainment was based on National Cholesterol Education program (NCEP) Adult Treatment Panel (ATP) III guidelines (2004). Newly Diagnosed Dyslipidemia Patients Including: 1)Intermediate Risk (&gt;2 Risk Factors) with Total Cholesterol above 200 mg/dL or Low Density Lipoprotein C (LDL-C) level &gt;130 who failed a 3-month diet control period, or 2) high risk patients with a history of coronary artery disease or diabetes having a total cholesterol &gt;200 mg/dl or LDL-C level &gt;130 mg/dl.</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>Intention-To-Treat (ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin 10/20 mg</title>
            <description>Ezetimibe/Simvastatin 10/20 mg tablet, once daily for the 6-week period</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 12-week Treatment.</title>
          <description>Goal attainment percentage of LDL-C after 12-week treatment. LDL-C goal attainment was based on National Cholesterol Education program (NCEP) Adult Treatment Panel (ATP) III guidelines (2004). Newly Diagnosed Dyslipidemia Patients Including: 1)Intermediate Risk (&gt;2 Risk Factors) with Total Cholesterol above 200 mg/dL or Low Density Lipoprotein C (LDL-C) level &gt;130 who failed a 3-month diet control period, or 2) high risk patients with a history of coronary artery disease or diabetes having a total cholesterol &gt;200 mg/dl or LDL-C level &gt;130 mg/dl.</description>
          <population>Intention-To-Treat (ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6</title>
        <time_frame>Baseline and week 6</time_frame>
        <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin 10/20 mg</title>
            <description>Ezetimibe/Simvastatin 10/20 mg tablet, once daily for the 6-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6</title>
          <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.4" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 6</title>
        <time_frame>Baseline and week 6</time_frame>
        <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin 10/20 mg</title>
            <description>Ezetimibe/Simvastatin 10/20 mg tablet, once daily for the 6-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 6</title>
          <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.1" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 6</title>
        <time_frame>Baseline and week 6</time_frame>
        <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin 10/20 mg</title>
            <description>Ezetimibe/Simvastatin 10/20 mg tablet, once daily for the 6-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 6</title>
          <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change of Triglycerides From Baseline at Week 6</title>
        <time_frame>Baseline and week 6</time_frame>
        <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin 10/20 mg</title>
            <description>Ezetimibe/Simvastatin 10/20 mg tablet, once daily for the 6-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change of Triglycerides From Baseline at Week 6</title>
          <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.2" lower_limit="-43.6" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6</title>
        <time_frame>Baseline and week 6</time_frame>
        <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin 10/20 mg</title>
            <description>Ezetimibe/Simvastatin 10/20 mg tablet, once daily for the 6-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6</title>
          <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-82.0" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin 10/20 mg</title>
            <description>Ezetimibe/Simvastatin 10/20 mg tablet, once daily for the 6-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12</title>
          <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.8" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 12</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin 10/20 mg</title>
            <description>Ezetimibe/Simvastatin 10/20 mg tablet, once daily for the 6-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 12</title>
          <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.5" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 12</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin 10/20 mg</title>
            <description>Ezetimibe/Simvastatin 10/20 mg tablet, once daily for the 6-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 12</title>
          <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change of Triglycerides From Baseline at Week 12</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin 10/20 mg</title>
            <description>Ezetimibe/Simvastatin 10/20 mg tablet, once daily for the 6-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change of Triglycerides From Baseline at Week 12</title>
          <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.7" lower_limit="-42.9" upper_limit="-3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin 10/20 mg</title>
            <description>Ezetimibe/Simvastatin 10/20 mg tablet, once daily for the 6-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12</title>
          <population>Intention-To-Treat(ITT) approach which included all participants who have baseline measurement, have taken at least one dose of the study drug, and have at least one post-baseline measurement</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-85.6" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ezetimibe/Simvastatin 10/20 mg</title>
          <description>Ezetimibe/Simvastatin 10/20 mg tablet, once daily for the 6-week period</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Peptic Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increased Creatine Phosphokinase (CPK)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Increased Serum Glutamic Pyruvic Transaminase (SGPT)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

